Teneligliptin Hydrobromide Intermedju CAS 401564-36-1 Purità > 99.5% (HPLC) Fabbrika
Provvista ta 'Teneligliptin Hydrobromide Intermedji Relatati B'Purità Għolja
Teneligliptin Hydrobromide CAS 906093-29-6
1-(3-Methyl-1-Phenyl-5-Pyrazolyl)piperazine CAS 401566-79-8
Teneligliptin Hydrobromide Intermedju CAS 401564-36-1
| Isem Kimiku | (2S)-4-Oxo-2-(3-thiazolidinylcarbonyl)-1-pyrrolidinecarboxylic acid tert-butyl ester |
| Sinonimi | (S)-tert-Butil 4-oxo-2-(thiazolidine-3-carbonyl)pyrrolidine-1-carboxylate;3-((S)-1-tert-butoxicarbonil-4-oxo-2-pirrolidinilkarbonil)-1,3-thiazolidine;(2S)-4-oxo-2-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidine-1-carboxylate;Teneligptin Intermedju B |
| Numru CAS | 401564-36-1 |
| Numru tal-KAT | RF-1818 |
| Status tal-istokk | Fil-Ħażna, Skala ta' Produzzjoni Sa Tunnellati |
| Formula Molekulari | C13H20N2O4S |
| Piż Molekulari | 300.37 |
| Densità | 1.305 |
| Brand | Ruifu Kimika |
| Oġġett | Standard ta' Spezzjoni | Riżultati |
| Dehra | Solidu kkulurit abjad għal krema | Konformi |
| Identifikazzjoni | IR;HPLC RT | Konformi |
| Telf fuq Tnixxif | <1.00% | 0.20% |
| Sustanzi Relatati | Kwalunkwe Impurità Unika <0.50% | 0.24% |
| Impurità totali <0.50% | 0.39% | |
| Assaġġ | 99.5% ~ 102.0% (Fuq Bażi Mnixxfa) | 99.8% |
| Purità Enantiomerika | >99.5% | 99.9% |
| Irmied sulfatat | <0.20% | 0.02% |
| Standard tat-Test | Standard tal-Intrapriża | |
| Użu | Intermedji ta' Tenelgliptin Hydrobromide (CAS: 906093-29-6) | |
Pakkett: Flixkun, borża tal-fojl tal-aluminju, 25kg/Drum tal-Kartun, jew skont il-ħtieġa tal-klijent
Kundizzjoni tal-Ħżin:Aħżen f'kontenituri ssiġillati f'post frisk u niexef;Ipproteġi mid-dawl u l-umdità
(2S)-4-Oxo-2-(3-thiazolidinylcarbonyl)-1-pyrrolidinecarboxylic acid tert-butyl ester (CAS: 401564-36-1) huwa intermedju użat biex jipprepara inibitur tad-dipeptidyl peptidase IV (DPP-IV), intermedji ta 'Teneligliptin Hydrobromide (CAS: 906093-29-6).Teneligliptin huwa inibitur DPP-4 li ġie approvat fil-Ġappun fl-2012 għat-trattament tad-dijabete tat-tip II.Ġie skopert u żviluppat minn Mitsubishi Tanabe Pharma taħt l-isem kummerċjali Tenelia®.Simili għal inibituri DPP-4 oħra fis-suq, Teneligliptin kien ittollerat tajjeb fl-istudji kollha u d-dożaġġ QD ipproduċa azzjoni inibitorja fit-tul kontra DPP-4 u żieda fil-livelli attivi ta’ GLP-1, b’rati baxxi ħafna ta’ eskrezzjoni renali.
